PT-141
A melanocortin peptide best known in regulated medicine as bremelanotide and in the research market as PT-141.
Also referenced as: Bremelanotide, Vyleesi
Also appears in: Skin & Cosmetic
This peptide maps to at least one regulated medical product or label context in the United States.
Primary lane: Hormone. Also surfaces under Skin & Cosmetic for browsing and discovery.
Bremelanotide, Vyleesi
FDA label signal · 10 trials · 104 PubMed results
What PT-141 is
PT-141 is the research-market name most people use for bremelanotide, a melanocortin peptide that also exists in FDA-approved drug form.
Why it matters
It is a strong example of why peptide names, aliases, and marketed use cases can drift apart. The same underlying compound may be discussed very differently in medical versus vendor contexts.
Regulatory context
Bremelanotide has FDA approval in the United States for a specific labeled use. That does not mean every PT-141 product sold online maps to an approved product or indication.
Practical reading note
Whenever a peptide has both an approved pharmaceutical identity and a research-market nickname, the safest reading starts with the approved label and works outward from there.